The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape

8 min

Published on: Aug 12, 2026

The clinical and commercial trajectory of antibody-drug conjugates (ADCs) marks a major shift in modern oncology. Twenty three ADCs have received approval in global markets, collectively accounting for more than 50 approved indications, with post-approval label expansions contributing substantially to the growth of the field and the transformation of treatments for solid tumors and hematologic malignancies.1 However, clinical reality reveals a core challenge: while antibody-drug conjugates deliver potent cytotoxic payloads directly to tumor cells, they have narrow therapeutic indices and are rarely curative as monotherapies. This benefit-risk tension has driven heightened regulatory oversight along the entire ADC development lifecycle.

Global health authorities—including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China's National Medical Products Administration (NMPA)—are moving away from traditional early oncology development models. Regulators demand rigorous safety oversight, mandatory dose optimization, and robust confirmatory trial planning from the earliest phases of clinical investigation—expectations that directly affect how ADC programs must be designed, resourced, and executed.

To navigate next-generation development and meet evolving global expectations, sponsors must adopt an integrated, cross-functional development strategy. This framework aligns translational science, nonclinical development, regulatory strategy, clinical pharmacology, safety monitoring, chemistry, manufacturing, and controls (CMC) readiness, and global trial design from the earliest stages of development.

Return to Insights Center

Related Insights

Blog

FDA novel oncology drug approvals in 2025: Trends and strategic insights for developers

Mar 31, 2026

Playbook

Preparing clinical infrastructure for radiopharmaceutical trials

Mar 11, 2026

Webinar

Accelerating delivery of radiopharmaceutical trials

Oct 3, 2025

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Webinar

Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

Nov 12, 2024

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Case Study

Speed meets strategy: Delivering a critical FDA 1572 package in just seven days

Sep 9, 2026

Blog

Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors

Aug 25, 2026

Related Insights

Blog

FDA novel oncology drug approvals in 2025: Trends and strategic insights for developers

Mar 31, 2026

Playbook

Preparing clinical infrastructure for radiopharmaceutical trials

Mar 11, 2026

Webinar

Accelerating delivery of radiopharmaceutical trials

Oct 3, 2025

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Webinar

Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

Nov 12, 2024

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Case Study

Speed meets strategy: Delivering a critical FDA 1572 package in just seven days

Sep 9, 2026

Blog

Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors

Aug 25, 2026

Show more

Back

Access exclusive insights

Harness the power of clinical development with exclusive insights from our experts at Parexel

Would you like to hear from us in the future?

Stay connected with Parexel!

Accept

Decline